Latest news
Debiopharm investit pour les médicaments innovants de demain – Inauguration de Campus “après-demain”, son site de développement et de production
Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate For Cancer Treatment
Doctor Manel Esteller Receives the Debiopharm Life Sciences Award For his Outstanding Research in Epigenetic Oncology
Le “Prix Debiopharm/Valais pour les Sciences de la Vie” honore un chimiste valaisan pour son procédé électrochimique novateur
Debiopharm Signs License Agreement for Marketing of Salvacyl®/Moapar 3-month for Sexual Deviations
Clinical Update – Debio 025 in Hepatitis C – Presentation of Phase IIa Efficacy Results
Debiopharm and Airmid Sign Option and License Agreement for the Development of Debio 0824, an ShK Peptide for Autoimmune Disorders
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.